Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Diffusion Pharmaceuticals Inc DFFN

Healthcare Biotechnology
Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to the areas. Its advanced product candidate, Trans Sodium Crocetinate (TSC), is developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine... see more

Recent & Breaking News (NDAQ:DFFN)

Diffusion Pharmaceuticals to Present at 18th Annual Rodman & Renshaw Global Investment Conference

GlobeNewswire September 9, 2016

Diffusion Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

GlobeNewswire August 18, 2016

Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial Second Quarter 2016 Results

GlobeNewswire August 15, 2016

Diffusion Pharmaceuticals Appoints Biotech Industry Veteran Isaac Blech to Board of Directors

GlobeNewswire August 15, 2016

Diffusion Pharmaceuticals Announces Acceptance of Abstract on Use of TSC in Hypoxia Driven Medical Emergencies at ACEP 2016 Research Forum

GlobeNewswire July 6, 2016

Diffusion Pharmaceuticals Expands Patent Estate of TSC as Therapeutic in Five Hypoxia-Related Indications

GlobeNewswire June 8, 2016

Diffusion Pharmaceuticals to Present at JMP Securities Life Sciences Conference

GlobeNewswire June 1, 2016

Diffusion Pharmaceuticals Provides Corporate Highlights and Reports First Quarter 2016 Results

GlobeNewswire May 16, 2016

Diffusion Pharmaceuticals Announces Publication of TSC Phase 1/2 Glioblastoma Multiforme Trial Data in the Journal of Neurosurgery

GlobeNewswire May 13, 2016

Diffusion Pharmaceuticals to Present at the 2016 BFC Global Healthcare Business Development and Investment Conference

GlobeNewswire April 13, 2016

Diffusion Pharmaceuticals Appoints Thomas Byrne as General Counsel

GlobeNewswire April 1, 2016

Diffusion Pharmaceuticals' CEO David Kalergis Interviewed by The Life Sciences Report

Marketwired March 31, 2016

Diffusion Pharmaceuticals Provides Corporate Highlights and Reports 2015 Financial Results

GlobeNewswire March 28, 2016

Diffusion Pharmaceuticals Announces Publication of RES-529 Review Article in Anti-Cancer Drugs

GlobeNewswire March 15, 2016

Diffusion Pharmaceuticals Announces Presentation at BIO CEO & Investor Conference

GlobeNewswire January 26, 2016

Diffusion Pharmaceuticals Announces Stock Ticker Symbol Change to DFFN

GlobeNewswire January 25, 2016